High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
JTO Clin Res Rep
; 3(6): 100328, 2022 Jun.
Article
in En
| MEDLINE
| ID: mdl-35637759
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
JTO Clin Res Rep
Year:
2022
Document type:
Article
Country of publication:
Estados Unidos